This market resolves to Yes if IDEAYA Biosciences publicly releases the topline results of the Phase 2/3 OptimUM-02 trial for HLA-A2*-negative metastatic uveal melanoma by September 30, 2026. The announcement must be verifiable through a public or press release from IDEAYA Biosciences or a reputable news source. If no such announcement is made by the specified date, this market will resolve to No.